Home
About us
Editorial board
Ahead of print
Browse Articles
Search
Submit article
Instructions
Subscribe
Contacts
Login
Advanced Search
Users Online: 363
» Articles published in the past year
To view other articles click corresponding year from the navigation links on the left side.
All
|
Case Report
|
Case Reports
|
Editorial
|
Erratum
|
Letter To Editor
|
Letters to Editor
|
Mini Review
|
Notice of Retraction
|
Original Article
|
Original Articles
|
Review Article
|
Review Articles
|
Short Communication
|
Short Communications
|
Systematic Review
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Show all abstracts
Show selected abstracts
Export selected to
Add to my list
Review Article:
Anticoagulation therapy in COVID-19 patients with chronic kidney disease
Mohammad Ali Shafiee, Sayyideh Forough Hosseini, Mojgan Mortazavi, Anahita Emami, Mahtab Mojtahed Zadeh, Sanaz Moradi, Pouyan Shaker
J Res Med Sci
2021, 26:63 (30 August 2021)
DOI
:10.4103/jrms.JRMS_875_20
Coagulopathy and derangements in the coagulation parameters are significant features of COVID-19 infection, which increases the risk of disseminated intravascular coagulation, thrombosis, and hemorrhage in these patients, resulting in increased morbidity and mortality. In times of COVID-19, special consideration should be given to patients with concurrent chronic kidney disease (CKD) and COVID-19 (CKD/COVID-19 patients) as renal dysfunction increases their risk of thrombosis and hemorrhage, and falsely affects some of the coagulation factors, which are currently utilized to assess thrombosis risk in patients with COVID-19. Hence, we believe extra attention should be given to determining the risk of thrombosis and bleeding and optimizing the timing and dosage of anticoagulant therapy in this unique population of patients. CKD/COVID-19 patients are considered a high-risk population for thrombotic events and hemorrhage. Furthermore, effects of renal function on paraclinical and clinical data should be considered during the evaluation and interpretation of thrombosis risk stratification. Individualized evaluation of clinical status and kidney function is necessary to determine the best approach and management for anticoagulant therapy, whereas there is a lack of studies about the population of CKD/COVID-19 patients who need anticoagulant therapy now.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Citations (3) ]
[Sword Plugin for Repository]
Beta
Advanced Search
Month wise articles
Figures next to the month indicate the number of articles in that month
2022
July
[
2
]
May
[
1
]
April
[
1
]
March
[
2
]
February
[
1
]
2021
October
[
2
]
September
[
3
]
August
[
1
]
July
[
2
]
June
[
2
]
May
[
2
]
March
[
4
]
February
[
3
]
2020
December
[
1
]
November
[
3
]
August
[
2
]
July
[
1
]
June
[
4
]
April
[
2
]
March
[
1
]
2019
December
[
1
]
October
[
2
]
August
[
2
]
July
[
1
]
May
[
1
]
April
[
3
]
March
[
1
]
February
[
1
]
January
[
2
]
2018
December
[
1
]
October
[
2
]
September
[
1
]
August
[
1
]
July
[
2
]
June
[
2
]
April
[
1
]
March
[
3
]
February
[
1
]
January
[
3
]
2017
December
[
1
]
November
[
1
]
Sitemap
|
What's New
Feedback
|
Copyright and Disclaimer
|
Privacy Notice
© Journal of Research in Medical Sciences | Published by Wolters Kluwer -
Medknow
Online since 9
th
February, 2015